A Phase 2 interventional study of FE 999049 and Placebo in Male Idiopathic Infertility, sponsored by Ferring Pharmaceuticals. Terminated at 22 sites in 7 countries. Open to male participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Ferring Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing follitropin delta in Infertility — 1 open to participants now, 1 under way, none of them phase 3. follitropin delta · Infertility.
Among the 13 studies testing follitropin delta in Infertility, this one is the 13th largest by enrollment, is one of 2 that started in 2022, is one of 5 in phase 2, and was the 12th registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →1 of the 13 studies testing follitropin delta in Infertility is open now, in 1 country. Recruiting first, the newest first:
Centre Hospitalier Intercommunal Creteil · Sites in France
Ages 18–38 · Women only
By country, each count listing its studies:
follitropin delta: first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 50 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2022.
This study's enrollment of 4 is below the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 220 across the 13 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 4 most frequent:
Ferring Pharmaceuticals is the lead sponsor of 249 studies on the registry; 4 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 14 (93%) have results posted.
39 studies in Infertility by Ferring Pharmaceuticals: none open now, 2 under way, none of them phase 3. Of 35 finished, 18 (51%) have results posted.
Among the 39 studies in Infertility by Ferring Pharmaceuticals, this one is the 25th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2022, is one of 6 in phase 2, and was the 33rd registered.
Ferring Pharmaceuticals’s Infertility studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing follitropin delta in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Ferring Pharmaceuticals’s 39 in Infertility:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this trial is to investigate whether men with idiopathic infertility (unexplained reduction of semen quality), after being treated with a daily dose of 12 µg recombinant follicle stimulating hormone (rFSH) for 6 months, can improve the chance of spontaneous pregnancy observed in their female partners in comparison to placebo (inactive treatment). For more information, please visit the trial's website www.adamclinicaltrial.com (only applicable in the US).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Current partner fulfilling the criteria below:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: FE 999049
Drug: Placebo
FE 999049 is administered as single daily subcutaneous injections of 12 μg for 6 months.
Also known as: REKOVELLE, Follitropin Delta
Placebo is administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049 for 6 months.
Spontaneous Pregnancy Observed in Female Partner Within 9 Months After Randomization of Male Subject, Where Spontaneous Pregnancy is Defined as Vital Pregnancy
Vital pregnancy is documentation of at least one intrauterine gestational sac with fetal heartbeat by ultrasound.
Time frame: Up to 9 months after randomization
Positive Beta-Human Chorionic Gonadotropins (βhCG) (Positive Urine βhCG Test) Observed in Female Partner
Time frame: Up to 9 months (End-of-Trial)
Time From Randomization to Spontaneous Pregnancy Observed in Female Partner.
Time frame: 9 months
Changes in Semen Volume From Pre-randomisation to 9 Months After Randomization
Change from baseline pre-randomisation to end of trial, which is 9 months.
Time frame: From pre-randomisation to end of trial (9 months)
Changes in Sperm Concentration
Change from baseline from pre-randomisation to end of trial, which is 9 months
Time frame: From pre-randomization to end of trial (9 months)
Changes in Total Sperm Count
Change from baseline from pre-randomisation to end of trial, which is 9 months
Time frame: From pre-randomisation to end of trial (9 months)
Changes in Total Motile Sperm Count
Change from baseline from pre-randomisation to end of trial, which is 9 months
Time frame: From pre-randomisation to end of trial (9 months)
Changes in Sperm Morphology
Change from baseline from pre-randomisation to end of trial, which is 9 months
Time frame: From pre-randomisation to end of trial (up to 9 months)
Changes in Semen DNA Fragmentation
Time frame: From pre-randomization to end of treatment
Treatment Responders Defined by Either Spontaneous Pregnancy Observed in Female Partner, or Increase of Total Sperm Count or Total Motile Sperm Count to 50% Over Average Baseline at 6 and/or 9 Months
Time frame: Baseline to 6 and 9 months
Changes in Follicle Stimulating Hormone (FSH)
Change from baseline.
Time frame: From randomization to 6 months after randomization
Changes in Luteinising Hormone (LH)
From randomisation to 3 and 6 months
Time frame: From randomisation to 3 and 6 months after randomization
Changes in Inhibin B
Change from baseline.
Time frame: From randomization to 6 months after randomization
Changes in Testosterone
Change from baseline.
Time frame: From randomization to 6 months after randomization
Changes in Estradiol
Change from baseline.
Time frame: From randomization to 6 months after randomization
Changes in Free Testosterone Concentration
Blood samples for assessment of sex hormone binding globulin (SHBG) concentrations will be drawn in order to calculate change from baseline in free testosterone concentrations.
Time frame: From randomization to 6 months after randomization
Number of Participants With Treatment-induced Anti-FSH Antibodies, Overall as Well as With Neutralising Capacity
Blood samples for assessment of anti-FSH antibodies will be drawn.
Time frame: From randomization to 21-35 days after End-of-treatment (9 months)
Number of Participants With Immune-related Adverse Events
All treatment-emergent adverse events will be analyzed to identify those that potentially are immune related.
Time frame: From randomization to End-of-Trial (up to 9 months)
| Milestone | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Started | 1 | 3 |
| Completed | 1 | 3 |
| Not completed | 0 | 0 |
Vital pregnancy is documentation of at least one intrauterine gestational sac with fetal heartbeat by ultrasound.
| Participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Spontaneous Pregnancy Observed in Female Partner Within 9 Months After Randomization of Male Subject, Where Spontaneous Pregnancy is Defined as Vital Pregnancy | 0 | 0 |
| Participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Positive Beta-Human Chorionic Gonadotropins (βhCG) (Positive Urine βhCG Test) Observed in Female Partner | 0 | 0 |
| Days | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Time From Randomization to Spontaneous Pregnancy Observed in Female Partner. | — | NA |
Change from baseline pre-randomisation to end of trial, which is 9 months.
| mL | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Changes in Semen Volume From Pre-randomisation to 9 Months After Randomization | 0.5 (0.5 to 0.5) | -1.25 (-2.5 to 0.95) |
Change from baseline from pre-randomisation to end of trial, which is 9 months
| x10^6 sperm/mL | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Changes in Sperm Concentration | -2.14 (-2.14 to -2.14) | -0.7 (-1.2 to 2.0) |
Change from baseline from pre-randomisation to end of trial, which is 9 months
| x10^6 sperm | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Changes in Total Sperm Count | -13.01 (-13.01 to -13.01) | -3.75 (-15.9 to -0.75) |
Change from baseline from pre-randomisation to end of trial, which is 9 months
| x10^6 sperm | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Changes in Total Motile Sperm Count | -3.74 (-3.74 to -3.74) | -0.965 (-3.71 to 0.24) |
Change from baseline from pre-randomisation to end of trial, which is 9 months
| % of sperm with normal shape | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Changes in Sperm Morphology | — | 0.0 (-2.0 to 5.0) |
No measurements were reported for this outcome.
| Participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Treatment Responders Defined by Either Spontaneous Pregnancy Observed in Female Partner, or Increase of Total Sperm Count or Total Motile Sperm Count to 50% Over Average Baseline at 6 and/or 9 Months | 0 | 2 |
Change from baseline.
| IU/L | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Changes in Follicle Stimulating Hormone (FSH) | 2.10 (2.10 to 2.10) | 0.10 (-0.50 to 2.30) |
From randomisation to 3 and 6 months
| IU/L | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| 3 months | -0.76 (-0.76 to -0.76) | -0.46 (-0.61 to -0.22) |
| 6 months | 1.23 (1.23 to 1.23) | 0.28 (-0.37 to 1.85) |
Change from baseline.
| pg/mL | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Changes in Inhibin B | 28.0 (28.0 to 28.0) | -4.0 (-19.0 to 16) |
Change from baseline.
| nmol/L | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Changes in Testosterone | 6.25 (6.25 to 6.25) | -0.35 (-2.43 to 4.85) |
Change from baseline.
| pmol/L | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Changes in Estradiol | 47.5 (47.5 to 47.5) | 33.0 (0.0 to 69.0) |
Blood samples for assessment of sex hormone binding globulin (SHBG) concentrations will be drawn in order to calculate change from baseline in free testosterone concentrations.
| nmol/L | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Changes in Free Testosterone Concentration | 6.25 (6.25 to 6.25) | -0.35 (-2.43 to 4.85) |
Blood samples for assessment of anti-FSH antibodies will be drawn.
| Participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Number of Participants With Treatment-induced Anti-FSH Antibodies, Overall as Well as With Neutralising Capacity | 0 | 0 |
All treatment-emergent adverse events will be analyzed to identify those that potentially are immune related.
| Participants | FE 999049 (Follitropin Delta) | Placebo |
|---|---|---|
| Number of Participants With Immune-related Adverse Events | 0 | 0 |
Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FE 999049 (Follitropin Delta) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Placebo | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Age, Customized(Participants) | FE 999049 (Follitropin Delta) | Placebo | Total |
|---|---|---|---|
| 18 - 50 years | 1 | 3 | 4 |
| Sex: Female, Male(Participants) | FE 999049 (Follitropin Delta) | Placebo | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 1 | 3 | 4 |
| Race (NIH/OMB)(Participants) | FE 999049 (Follitropin Delta) | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 1 | 3 | 4 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2022 to primary completion in Oct 2024, 25 months.
Results were first posted in Aug 2026, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin delta